Table 2 Cumulative Incidence, SIRs, EARs, and latency of subsequent neoplasms.

From: Increased risk of subsequent neoplasm after hematopoietic stem cell transplantation in 5-year survivors of childhood acute lymphoblastic leukemia

Type of subsequent neoplasm

ICD-O-3 code

Cases

SIR (95% CI)

AER/10.000 PY

30-year Cumulative Incidence (95% CI)

Median latency (range), yearsa

Total SMNsb

 

97

2.6 (2.1–3.1)

10.0

3.8 (2.9–4.9)

26.5 (5.8–46.1)

Solid tumors

C000–C809

87

2.7 (2.2–3.4)

9.3

3.4 (268–4.4)

26.5 (5.8–46.1)

 Head and neck

C000–149, C300–C329, C690–C699

10

11.1 (5.3–20.4)

1.5

0.2 (0.07–0.5)

31.2 (9.3–41.6)

 Digestive organsc

C150–C269

9

24.8 (11.3–47.0)

1.4

0.4 (0.2–1.0)

29.5 (19.9–39.0)

 Pulmonaryd

C339–C349, C384, C390–C399

2

1.5 (0.2–5.5)

0.3

0.05 (0.007–0.4)

30.8 (19.0–42.7)

 Bone

C400–C419

5

6.6 (2.2–15.5)

0.1

0.1 (0.06–0.4)

13.4 (6.8–33.0)

 Soft tissuee

C470–C499

6

8.0 (2.9–17.5)

0.9

0.3 (0.1–0.7)

22.1 (9.0–31.1)

 Female breastf

C500–C509

10

1.3 (0.6–2.3)

0.4

0.4 (0.2–0.9)

29.2 (13.1–39.8)

 Female genital organsg

C510–C589

4

1.5 (0.4–4.0)

0.2

0.07 (0.01–0.5)

35.2 (23.8–46.1)

 Male genital organs

C600–C639

3

0.7 (0.1–2.0)

−0.2

0.07 (0.01–0.5)

17.3 (6.3–44.3)

 Testis

C620–C629

2

0.5 (0.06–1.8)

−0.4

0.08 (0.02–0.3)

11.8 (6.3–17.3)

 Central nervous system

C700–C729

15

9.2 (5.1–15.1)

2.2

0.6 (0.4–1.2)

26.2 (5.8–37.6)

 Brain

C710–C719

7

4.6 (1.8–9.4)

0.9

0.3 (0.1–0.8)

28.6 (11.5–37.8)

 Meninges

C700–C709

5

360 (117.0–841.1)

0.8

0.2 (0.06–0.7)

28.0 (16.3–37.6)

 Thyroid

C730–C739, C323,

13

10.9 (5.8–18.5)

2.0

0.6 (0.3–1.2)

28.4 (10.8–33.9)

 Melanomah

C44, C69—M8720–M8790

12

2.4 (1.3–4.0)

1.3

0.5 (0.3–1.1)

26.5 (11.8–40.8)

 Nonmelanoma skin (BCC excluded)

C44 excluding M8720–M8790

4

4.0 (1.1–10.4)

0.5

0.09 (0.02–0.4)

25.4 (12.6–30.8)

Hematological

C42, C77—M9591–M9948

10

1.7 (0.8–3.2)

0.7

0.4 (0.2–0.9)

25.2 (15.7–42.7)

 Leukemias

C42—M9800–M9948

2

1.1 (0.1–3.8)

0.02

0.05 (0.006–0.3)

26.2 (17.7–34.7)

 Myeloid

M9840–M9948

1

1.3 (0.03–7.5)

0.04

0

34.7 (34.7–34.7)

 Lymphoblastic

M9811–M9837

1

1.0 (0.03–5.7)

0.01

0.05 (0.006–0.3)

17.7 (17.7–17.7)

 Lymphomas

C77—M9591–M9738

7

3.8 (1.5–7.7)

0.9

0.4 (0.2–0.8)

25.2 (15.7–37.3)

 Non-Hodgkin lymphoma

M9591, M9670–M9738

5

2.9 (0.9–6.7)

0.5

0.2 (0.09–0.6)

25.2 (15.8–37.3)

 Hodgkin-lymphoma

M9650–M9667

2

1.0 (0.1–3.7)

0.0

0.1 (0.03–0.5)

21.2 (15.7–26.7)

 Other hematologic

M9732

1

6.3 (0.2–24.9)

0.1

0

42.7 (42.7–42.7)

Total SNMNs

 

267

NA

NA

9.9 (8.5–11.5)

25.6 (5.5–48.3)

Colorectal

C18–C21

27

NA

NA

0.9 (0.5–1.6)

29.3 (14.8–44.2)

Liver adenoma

C22.0

1

NA

NA

0.04 (0.006–0.3)

15.4 (15.4–15.4)

Thyroid/parathyroid adenomas

C73.9, C75.0

12

NA

NA

0.7 (0.4–1.4)

24.7 (12.3–34.3)

Lipomas

M8850–M8881

35

NA

NA

1.7 (1.1–2.5)

25.8 (10.3–43.3)

Fibromas

M8391, M8810–M8836, M8965, M9013–M9030, M9321, M9540–9550

11

NA

NA

0.4 (0.2–0.8)

23.9 (12.6–38.8)

 Neurofibromas

M9540–M9550

3

NA

NA

0.09 (0.02–0.3)

16.9 (12.6–33.9)

Head and Neck

C00–C14, C30–C32, C69, C76.0

15

NA

NA

0.7 (0.4–1.3)

23.8 (5.9–48.3)

 Oral (squamous)

C03.0–C06.0/M8050–M8070, M808–M8081, M8560

4

NA

NA

0.2 (0.05–0.6)

23.6 (9.5–48.3)

Bone neoplasms

C40.0–41.9

18

NA

NA

0.7 (0.4–1.1)

13.4 (6.4–41.6)

 Osteoma

M9180–M9200

2

NA

NA

0

40.2 (38.7–41.6)

 Osteochondroma

M9210

2

NA

NA

0.5 (0.3–0.9)

10.7 (6.4–17.3)

 Chondroma

M9220–M9241

2

NA

NA

0.09 (0.02–0.3)

14.2 (11.8–16.7)

 Giant Cell tumor

M9250

2

NA

NA

0.09 (0.02–0.4)

16.7 (15.6–17.9)

Female breast

C50.0–50.9

28

NA

NA

1.0 (0.6–1.7)

27.7 (23.5–38.0)

 Fibroadenoma

M8392, M9010–M9011

21

NA

NA

0.8 (0.5–1.3)

14.5 (6.4–38.9)

 Ductal carcinoma in situ

M8500–M8505, M8507–M8522

7

NA

NA

0.2 (0.08–0.7)

32.9 (8.8–43.6)

Urogenital neoplasms

C51.0–C68.9

41

NA

NA

1.9 (1.3–2.8)

25.0 (7.3–41.6)

 Bladder

C67

1

NA

NA

(0.01–0.6)

25.7 (25.7–25.7)

 Female reproductive system

C51–C58

38

NA

NA

1.7 (1.2–2.6)

25.6 (7.3–41.6)

 Leiomyoma

M8890–M8898

8

NA

NA

0.2 (0.7–0.5)

18.8 (7.5–40.5)

 Cervical intra-epithelial neoplasm

M8077

22

NA

NA

1.3 (0.8–2.1)

25.8 (16.5–41.6)

 Male reproductive system

C60–C63

2

NA

NA

0.1 (0.03–0.4)

18.5 (15.0–22.0)

Central nervous system

C70, C71, C72

89

NA

NA

2.8 (2.0–3.9)

31.6 (6.1–46.2)

 Meningioma

M9150

81

NA

NA

2.5 (1.7–3.5)

32.2 (9.4–46.2)

 Schwannoma/neurinoma

M9560

3

NA

NA

0.1 (0.03–0.5)

25.1 (17.5–31.9)

Peripheral schwannoma

M9560 excluding CNS

6

NA

NA

0.3 (0.1–0.7)

18.6 (13.5–23.6)

Vascular, excluding CNSi

 

7

NA

NA

0.3 (0.1–0.7)

22.0 (5.5–38.1)

 Hemangioma

C49.0–49.9, C71.0–71.9/M9120–M9136, M9141. M9142

5

NA

NA

0.2 (0.04–0.6)

27.0 (7.5–38.1)

 Angioleiomyoma

C49.0–49.9 / M8894

2

NA

NA

0.5 (0.09–1.0

15.1 (7.5–22.6)

Subcutaneous, other

C49.0–49.9

9

NA

NA

0.3 (0.1–0.8)

28.9 (6.3–39.2)

Unspecified

M8000

1

NA

NA

0.04 (0.005–0.3)

7.3 (7.3–7.3)

Basal cell carcinoma

 

172

NA

NA

5.6 (4.5–7.0)

26.1 (5.6–43.5)

  1. Bold shows the overall numbers.
  2. ICD-O-3 International classification of disease for oncology, third edition, SMN Subsequent malignant neoplasm, SNMN Subsequent non-malignant neoplasm, SIR Standardized incidence ratio, AER absolute excess risk, PY Person years, CNS Central nervous system.
  3. aTime since childhood ALL diagnosis.
  4. bNine survivors developed multiple SMNs.
  5. cOne digestive tumor occurred as second SMN after a first thyroid carcinoma.
  6. dOne pulmonary occurred as second SMN after a first squamous cell carcinoma.
  7. eOne soft tissue occurred as second SMN after a first squamous cell carcinoma.
  8. fOne mamma carcinoma occurred as second SMN after a first ductal carcinoma in the other breast and one mamma carcinoma occurred after a thyroid carcinoma.
  9. gOne female genital organ tumor occurred as second SMN after a first mamma carcinoma.
  10. hOne melanoma occurred as second SMN after another melanoma and one melanoma after stomach carcinoma.
  11. iVascular neoplasms in the brain were not included in this category but in the “Central nervous system” category.
Back to article page